West Pharmaceutical Services (WST) EBITDA (2016 - 2025)
Historic EBITDA for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $156.6 million.
- West Pharmaceutical Services' EBITDA fell 187.97% to $156.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $584.9 million, marking a year-over-year increase of 263.2%. This contributed to the annual value of $584.9 million for FY2025, which is 263.2% up from last year.
- According to the latest figures from Q4 2025, West Pharmaceutical Services' EBITDA is $156.6 million, which was down 187.97% from $167.6 million recorded in Q3 2025.
- In the past 5 years, West Pharmaceutical Services' EBITDA registered a high of $228.4 million during Q2 2022, and its lowest value of $107.0 million during Q1 2025.
- In the last 5 years, West Pharmaceutical Services' EBITDA had a median value of $164.4 million in 2024 and averaged $165.9 million.
- In the last 5 years, West Pharmaceutical Services' EBITDA surged by 10395.75% in 2021 and then plummeted by 3084.93% in 2024.
- Quarter analysis of 5 years shows West Pharmaceutical Services' EBITDA stood at $184.0 million in 2021, then fell by 29.51% to $129.7 million in 2022, then increased by 24.06% to $160.9 million in 2023, then dropped by 0.81% to $159.6 million in 2024, then fell by 1.88% to $156.6 million in 2025.
- Its EBITDA was $156.6 million in Q4 2025, compared to $167.6 million in Q3 2025 and $153.7 million in Q2 2025.